BackNeumora Therapeutics Overview
Neumora Therapeutics Inc.

Neumora Therapeutics Debt to Equity

Neumora Therapeutics (NMRA) has a debt-to-equity ratio of 0.01, below the sector sector average of 0.13.

Get informed when a big investor buys or sells

+ Follow

Debt to Equity

0.01

Debt to Equity

0.01

Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.

Average Debt to Equity (Comparison Companies)

Loading

Debt to Equity History

Loading

Debt to Equity Comparison

Loading

Neumora Therapeutics (NMRA) FAQ

As of the most recent data, NMRA shows a debt-to-equity ratio of 0.01. That is below the sector sector average of 0.13. Scroll down for historical charts and peer comparison views.

The its sector sector average debt-to-equity ratio is about 0.13. Neumora Therapeutics is at 0.01, which is lower that average. That is roughly 95.6% below the sector mean. Use the comparison chart on this page to see how NMRA stacks up against individual peers as well.

Investors watch NMRA's debt-to-equity ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Neumora Therapeutics's latest reading is 0.01. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.

Besides this debt-to-equity ratio page, Stockcircle has Neumora Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect debt-to-equity ratio (currently 0.01) with ownership activity and broader fundamentals.